{"a":[{"_":"ADC Therapeutics' shares plummet after patient deaths in trial of Zynlonta","$":{"href":"/pharma/adcs-shares-plummet-after-patient-deaths-trial-zynlonta","hreflang":"en"}}]}
Data ReadoutnegativeZynlontaNegative
AI Analysis
Summary
ADC Therapeutics' Zynlonta showed three times as many deaths in the study arm compared to the control arm, raising serious safety questions about the FDA-approved antibody-drug conjugate and causing a significant stock decline.
Clinical Trial Data
Primary Endpoint
Not Met
Outcome Details
Three times as many deaths in the study arm versus the control arm
Importance:9/10
Sentiment:
-0.95
safety_concernpatient_deathsantibody-drug_conjugateaccelerated_approvaltrial_datastock_decline
Related Companies
Read the original article
Published by FiercePharma on June 4, 2026 11:12 AM